These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33093581)

  • 1. Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China.
    Ma L; Mi Y; Cui S; Wang H; Fu P; Yin Y; Jin F; Li J; Liu Y; Fan Z; Zhang H; Geng C; Jiang Z
    Sci Rep; 2020 Oct; 10(1):18132. PubMed ID: 33093581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal surveillance for postoperative metastasis in breast cancer patients.
    Makita M; Sakai T; Ogiya A; Kitagawa D; Morizono H; Miyagi Y; Iijima K; Iwase T
    Breast Cancer; 2016 Mar; 23(2):286-94. PubMed ID: 25294313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
    Klar N; Rosenzweig M; Diergaarde B; Brufsky A
    Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
    He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
    PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.
    Tan Y; Li X; Chen H; Hu Y; Jiang M; Fu J; Yuan Y; Ding K
    Oncotarget; 2016 Oct; 7(43):70991-71000. PubMed ID: 27542240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Ogiya R; Sagara Y; Niikura N; Freedman RA
    Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
    Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
    Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
    Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y
    Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast-Conserving Surgery in Bilateral Breast Cancer.
    O'Brien JA; Ho A; Wright GP; Stempel M; Patil S; Krause K; Morrow M; Gemignani ML
    Ann Surg Oncol; 2015 Oct; 22(10):3389-96. PubMed ID: 26265365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X; Fan Y; Xu B
    Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.